Search Results - "Mammoliti, Serafina"

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers by Biatta, Chiara M., Paudice, Michele, Greppi, Marco, Parrella, Veronica, Parodi, Alessia, De Luca, Giuseppa, Cerruti, Gianna Maria, Mammoliti, Serafina, Caroti, Cinzia, Menichini, Paola, Fronza, Gilberto, Pesce, Silvia, Marcenaro, Emanuela, Vellone, Valerio G.

“…Background we evaluated the concordance between immunohistochemical p53 staining and TP53 mutations in a series of HGSOC. Moreover, we searched for prognostic…”
Get full text

Neoadjuvant chemotherapy and vaginal radical trachelectomy for fertility-sparing treatment in women affected by cervical cancer (FIGO stage IB–IIA1) by Marchiole, Pierangelo, Tigaud, Jean-Dominique, Costantini, Sergio, Mammoliti, Serafina, Buenerd, Annie, Moran, Eva, Mathevet, Patrice

“…Abstract Objectives The aim of the present report is to support the feasibility and the safety of a new fertility-sparing treatment in young women affected by…”
Get full text

Neoadjuvant Chemotherapy Followed by Radical Surgery versus Concurrent Chemo-Radiotherapy in the Treatment of Locally Advanced Cervical Cancer: A Multicenter Retrospective Analysis by Sala, Paolo, Bogliolo, Stefano, Barra, Fabio, Fazio, Alessandra, Maramai, Mattia, Cassani, Chiara, Gardella, Barbara, Babilonti, Luciana, Giannelli, Flavio, Mammoliti, Serafina, Spinillo, Arsenio, Ferrero, Simone, Valenzano Menada, Mario, Costantini, Sergio, Bruzzi, Paolo, Marchiolè, Pierangelo

“…This study aims to evaluate oncological outcomes in women affected by locally advanced cervical cancer (LACC) treated by neoadjuvant chemotherapy before…”
Get full text

Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors by Arezzo, Francesca, Giannone, Gaia, Castaldo, Daniele, Scotto, Giulia, Tuninetti, Valentina, Turinetto, Margherita, Bartoletti, Michele, Mammoliti, Serafina, Artioli, Grazia, Mangili, Giorgia, Salutari, Vanda, Lorusso, Domenica, Cormio, Gennaro, Loizzi, Vera, Zamagni, Claudio, Savarese, Antonella, Di Maio, Massimo, Ronzino, Graziana, Pisano, Carmela, Pignata, Sandro, Valabrega, Giorgio

“…Endometrial cancer (EC) represents 3.4% of all newly diagnosed cancer cases and is responsible for 2.1% of all cancer-related deaths. Approximately 10%-15% of…”
Get full text

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors by Arezzo, Francesca, Giannone, Gaia, Castaldo, Daniele, Scotto, Giulia, Tuninetti, Valentina, Turinetto, Margherita, Bartoletti, Michele, Mammoliti, Serafina, Artioli, Grazia, Mangili, Giorgia, Salutari, Vanda, Lorusso, Domenica, Cormio, Gennaro, Loizzi, Vera, Zamagni, Claudio, Savarese, Antonella, Di Maio, Massimo, Ronzino, Graziana, Pisano, Carmela, Pignata, Sandro, Valabrega, Giorgio

“…[This corrects the article DOI: 10.3389/fonc.2023.1247291.]…”
Get full text

Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey by Giannone, Gaia, Castaldo, Daniele, Tuninetti, Valentina, Scotto, Giulia, Turinetto, Margherita, Valsecchi, Anna Amela, Bartoletti, Michele, Mammoliti, Serafina, Artioli, Grazia, Mangili, Giorgia, Salutari, Vanda, Lorusso, Domenica, Cormio, Gennaro, Zamagni, Claudio, Savarese, Antonella, Di Maio, Massimo, Ronzino, Graziana, Pisano, Carmela, Pignata, Sandro, Valabrega, Giorgio

“…Endometrial cancer (EC) therapeutic and diagnostic approaches have been changed by the development of a new prognostic molecular classification, the…”
Get full text

Histopathological and Immunohistochemical Prognostic Factors in High-Grade Non-Endometrioid Carcinomas of the Endometrium (HG-NECs): Is It Possible to Identify Subgroups at Increased Risk? by Paudice, Michele, Biatta, Chiara Maria, Scaglione, Giulia, Parodi, Alessia, Mammoliti, Serafina, Moioli, Melita, Centurioni, Maria Grazia, Barra, Fabio, Ferrero, Simone, De Cian, Franco, Mazzocco, Katia, Vellone, Valerio Gaetano

“…Endometrial cancer is an emerging disease with an increase in prevalence of aggressive histotypes in recent years. In the present study, potential…”
Get full text

Peritoneal carcinomatosis from ovarian paraganglioma: Report of a rare case and systematic review of the literature by Bizzarri, Nicolò, De Cian, Franco, Di Domenico, Stefano, Centurioni, Maria Grazia, Mammoliti, Serafina, Ghirardi, Valentina, Vellone, Valerio Gaetano

“…Paraganglioma is one of the rarest neoplasms involving the ovary, with only 10 previous reports. We present a case of peritoneal carcinomatosis from primary…”
Get full text

Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy: a case report by Giannelli, Flavio, Chiola, Ilaria, Belgioia, Liliana, Garelli, Stefania, Pastorino, Alice, Marcenaro, Michela, Mammoliti, Serafina, Costantini, Sergio, Bizzarri, Nicolò, Vellone, Valerio, Barra, Salvina, Corvò, Renzo

“…Hidradenocarcinoma (HC) is a very rare disease. This case report illustrates a successful treatment of a 60-year-old woman with vulvo-vaginal localization of…”
Get full text

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial by Cremolini, Chiara, Antoniotti, Carlotta, Rossini, Daniele, Lonardi, Sara, Loupakis, Fotios, Pietrantonio, Filippo, Bordonaro, Roberto, Latiano, Tiziana Pia, Tamburini, Emiliano, Santini, Daniele, Passardi, Alessandro, Marmorino, Federica, Grande, Roberta, Aprile, Giuseppe, Zaniboni, Alberto, Murgioni, Sabina, Granetto, Cristina, Buonadonna, Angela, Moretto, Roberto, Corallo, Salvatore, Cordio, Stefano, Antonuzzo, Lorenzo, Tomasello, Gianluca, Masi, Gianluca, Ronzoni, Monica, Di Donato, Samantha, Carlomagno, Chiara, Clavarezza, Matteo, Ritorto, Giuliana, Mambrini, Andrea, Roselli, Mario, Cupini, Samanta, Mammoliti, Serafina, Fenocchio, Elisabetta, Corgna, Enrichetta, Zagonel, Vittorina, Fontanini, Gabriella, Ugolini, Clara, Boni, Luca, Falcone, Alfredo, Falcone, Alfredo, Lonardi, Sara, De Braud, Filippo Guglielmo Maria, Bordonaro, Roberto, Maiello, Evaristo, Tamburini, Emiliano, Santini, Daniele, Frassineti, Giovanni Luca, Gamucci, Teresa, Aprile, Giuseppe, Zaniboni, Alberto, Granetto, Cristina, Buonadonna, Angela, Di Costanzo, Francesco, Tomasello, Gianluca, Gianni, Luca, Di Donato, Samantha, Carlomagno, Chiara, Clavarezza, Matteo, Racca, Patrizia, Mambrini, Andrea, Roselli, Mario, Allegrini, Giacomo, Sobrero, Alberto, Aglietta, Massimo, Corgna, Enrichetta, Cortesi, Enrico, Corsi, Domenico Cristiano, Ballestrero, Alberto, Bonetti, Andrea, Di Clemente, Francesco, Ruggeri, Enzo, Ciardiello, Fortunato, Benasso, Marco, Vitello, Stefano, Cinieri, Saverio, Mosconi, Stefania, Silvestris, Nicola, Frassoldati, Antonio, Cupini, Samantha, Bertolini, Alessandro, Tortora, Giampaolo, Bengala, Carmelo, Ferrari, Daris, Ardizzoia, Antonia, Milandri, Carlo, Chiara, Silvana, Romano, Gianpiero, Miraglia, Stefania, Scaltriti, Laura, Pucci, Francesca, Blasi, Livio, Brugnatelli, Silvia, Fioretto, Luisa, Ribecco, Angela Stefania, Longarini, Raffaella, Frisinghelli, Michela, Banzi, Maria

“…The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab showed improved outcomes for patients with metastatic colorectal…”
Get full text

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial by Pignata, Sandro, Lorusso, Domenica, Joly, Florence, Gallo, Ciro, Colombo, Nicoletta, Sessa, Cristiana, Bamias, Aristotelis, Salutari, Vanda, Selle, Frédèric, Frezzini, Simona, De Giorgi, Ugo, Pautier, Patricia, Bologna, Alessandra, Orditura, Michele, Dubot, Coraline, Gadducci, Angiolo, Mammoliti, Serafina, Ray-Coquard, Isabelle, Zafarana, Elena, Breda, Enrico, Favier, Laure, Ardizzoia, Antonio, Cinieri, Saverio, Largillier, Rémy, Sambataro, Daniela, Guardiola, Emmanuel, Lauria, Rossella, Pisano, Carmela, Raspagliesi, Francesco, Scambia, Giovanni, Daniele, Gennaro, Perrone, Francesco, Pignata, S, Lorusso, D, Joly, F, Gallo, C, Colombo, N, Sessa, C, Bamias, A, Salutari, V, Selle, F, Frezzini, S, De Giorgi, U, Pautier, P, Bologna, A, Orditura, M, Dubot, C, Gadducci, A, Mammoliti, S, Ray-Coquard, I, Zafarana, E, Breda, E, Favier, L, Ardizzoia, A, Cinieri, S, Largillier, R, Sambataro, D, Guardiola, E, Lauria, R, Pisano, C, Raspagliesi, F, Scambia, G, Daniele, G, Perrone, F

“…Bevacizumab is approved in combination with chemotherapy for the treatment of ovarian cancer, either in first-line therapy or for patients with recurrent…”
Get full text

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites by Colombo, Nicoletta, Mangili, Giorgia, Mammoliti, Serafina, Kalling, Mårten, Tholander, Bengt, Sternas, Lars, Buzenet, Giliane, Chamberlain, Donald

“…Abstract Objective The recombinant fusion protein, aflibercept binds and neutralizes vascular endothelial growth factor (VEGF) A, B and placental growth factor…”
Get full text

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial by Lorusso, Domenica, Raspagliesi, Francesco, Ronzulli, Dominique, Valabrega, Giorgio, Colombo, Nicoletta, Pisano, Carmela, Cassani, Chiara, Tognon, Germana, Tamberi, Stefano, Mangili, Giorgia, Mammoliti, Serafina, De Giorgi, Ugo, Greco, Filippo, Mosconi, Anna Maria, Breda, Enrico, Artioli, Grazia, Andreetta, Claudia, Casanova, Claudia, Ceccherini, Rita, Frassoldati, Antonio, Salutari, Vanda, Giolitto, Serena, Scambia, Giovanni

“…Literature evidence suggests that trabectedin monotherapy is effective in patients with recurrent ovarian cancer (OC) presenting mutation and/or BRCAness…”
Get full text

Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study by Tuninetti, Valentina, Virano, Elisa, Salutari, Vanda, Ricotti, Andrea, Pisano, Carmela, Ducceschi, Monika, Turitto, Giacinto, Scandurra, Giuseppa, Petrella, Maria Cristina, Forestieri, Valeria, Rizzetto, Monica, Mammoliti, Serafina, Artioli, Grazia, Cioffi, Raffaella, Borsotti, Lucia, Bellero, Marco, Rognone, Chiara, Carbone, Vittoria, Ferrandina, Gabriella, Mantiero, Mara, Azzolina, Carmen, Geninatti, Eleonora, Pignata, Sandro, Valabrega, Giorgio

“…cemiplimab is an immunoglobulin G4 monoclonal antibody targeting the programmed cell death-1 receptor. A nominal use program is available in Italy in advanced…”
Get full text

Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study by Colombo, Nicoletta, Gadducci, Angiolo, Landoni, Fabio, Lorusso, Domenica, Sabbatini, Roberto, Artioli, Grazia, Berardi, Rossana, Ceccherini, Rita, Cecere, Sabrina Chiara, Cormio, Gennaro, De Angelis, Carmine, Legge, Francesco, Lissoni, Andrea, Mammoliti, Serafina, Mangili, Giorgia, Naglieri, Emanuele, Petrella, Maria Cristina, Ricciardi, Giuseppina Rosaria Rita, Ronzino, Graziana, Salutari, Vanda, Sambataro, Daniela, Savarese, Antonella, Scandurra, Giuseppa, Tasca, Giulia, Tomao, Federica, Valabrega, Giorgio, Zavallone, Laura, Pignata, Sandro

“…•Several treatment options for ovarian carcinoma are available beyond chemotherapy (83).•Maintenance therapy with bevacizumab and/or PARPi can prolong survival…”
Get full text

Reliability of patient-reported toxicities during adjuvant chemotherapy by Cremante, Malvina, Pastorino, Alessandro, Ponzano, Marta, Grassi, Massimiliano, Martelli, Valentino, Puccini, Alberto, Catalano, Fabio, Murianni, Veronica, Iaia, Maria L., Puglisi, Silvia, Gandini, Annalice, Fornarini, Giuseppe, Caprioni, Francesco, Andretta, Valeria, Pessino, Annamaria, Comandini, Danila, Sciallero, Maria S., Mammoliti, Serafina, Sormani, Maria P., Sobrero, Alberto

“…Patient-reported outcomes (PROs) are validated tools to assess the impact of efficacy and toxicities of cancer treatments on patients’ health status. Because…”
Get full text

Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) by Marchetti, Claudia, Ferrandina, Gabriella, Cormio, Gennaro, Gambino, Angela, Cecere, Sabrina, Lorusso, Domenica, De Giorgi, Ugo, Bogliolo, Stefano, Fagotti, Anna, Mammoliti, Serafina, Narducci, Filomena, Bergamini, Alice, Scollo, Paolo, Biglia, Nicoletta, Breda, Enrico, Tamberi, Stefano, Marinaccio, Marco, Angioli, Roberto, Salerno, Laura, Eusebi, Maria Chiara, Loizzi, Vera, Scambia, Giovanni, Panici, Pierluigi Benedetti

“…Abstract Background Brain metastases (BM) from epithelial ovarian cancer (EOC) are considered a rare and unfavourable event. There is no consensus regarding…”
Get full text

Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23) by Scambia, Giovanni, Raspagliesi, Francesco, Valabrega, Giorgio, Colombo, Nicoletta, Pisano, Carmen, Cassani, Chiara, Tognon, Germana, Tamberi, Stefano, Mangili, Giorgia, Mammoliti, Serafina, De Giorgi, Ugo, Greco, Filippo, Mosconi, Anna Maria, Breda, Enrico, Artioli, Grazia, Andreetta, Claudia, Casanova, Claudia, Ceccherini, Rita, Frassoldati, Antonio, Lorusso, Domenica

“…LBA5504 Background: Trabectedin demonstrated antitumor activity when administered as single agent in relapsed platinum sensitive ovarian cancer (OC), with an…”
Get full text

Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society by Milani, Andrea, Tuninetti, Valentina, Pignata, Sandro, Lorusso, Domenica, Castaldo, Daniele, De Giorgi, Ugo, Savarese, Antonella, Biglia, Nicoletta, Scandurra, Giuseppa, Mangili, Giorgia, Di Maio, Massimo, Turinetto, Margherita, Bellero, Marco, Mammoliti, Serafina, Testa, Silvia, Scotto, Giulia, Purro, Andrea, Artioli, Grazia, Valabrega, Giorgio

“…Introduction: Low molecular weight heparin (LMWH) has been the backbone of the treatment of cancer associated thrombosis (CAT). Direct-acting oral…”
Get full text

The prognostic value of FIGO staging defined by combining MRI and [ 18 F]FDG PET/CT in patients with locally advanced cervical cancer by Raffa, Stefano, Lanfranchi, Francesco, Satragno, Camilla, Giannelli, Flavio, Marcenaro, Michela, Coco, Angela, Cena, Sofia Elizabeth, Sofia, Luca, Marini, Cecilia, Mammoliti, Serafina, Levaggi, Alessia, Tagliafico, Alberto Stefano, Sambuceti, Gianmario, Barra, Salvina, Morbelli, Silvia, Belgioia, Liliana, Bauckneht, Matteo

“…The last version of the FIGO classification recommended imaging tools to complete the clinical assessment of patients with cervical cancer. However, the…”
Get full text